Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Related MRK
Merck Issues Statement Related to Role of PNEUMOVAX 23 in Updated ACIP Recommendations
UPDATE: FDA Approves Belsomra Tablets for Use as Sleep Aid
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters